A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. (Q53359316)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. |
scientific article |
Statements
A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma. (English)
1 reference
Branimir I Sikic
1 reference
Lynn Hartmann
1 reference
Ranjana Advani
1 reference
Prema Peethambaram
1 reference
Bert L Lum
1 reference
George A Fisher
1 reference
Harry J Long
1 reference
Joanne Halsey
1 reference
Jon T Holmlund
1 reference
Andrew Dorr
1 reference
1 January 2004
1 reference
1 reference
100
1 reference
321-326
1 reference
2
1 reference
Identifiers
1 reference